Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2019, Vol. 24 ›› Issue (3): 355-360.doi: 10.12092/j.issn.1009-2501.2019.03.020

Previous Articles    

Sodium calcium exchanger and renal ischemia reperfusion injury

CHEN Chaohu 1, ZHUANG Hua 2, YAO Zhiqiang 1, HAN Dali 1, CHANG Cheng 1, MA Zhongyi 1, KONG Xiangbing 1, CAO Jinlong 1, LI Pan 1, TIAN Junqiang 1   

  1. 1 Lanzhou University Second Hospital, Lanzhou 730030, Gansu, China; 2 Gansu Second People's Hospital Blood Purification Center, Lanzhou 730030, Gansu, China
  • Received:2018-10-23 Revised:2018-12-07 Online:2019-03-26 Published:2019-04-01

Abstract:

Sodium calcium exchanger (NCX), which is widely expressed in the plasma membrane, mitochondrial membrane and secretory vesicles in diverse kinds of cells, belongs to a type of cation translocators. NCX works in two modes, the forward mode and reverse mode. Exactly through the two-way modes, NCX can regulate intracellular Ca2+ concentration fleetly and accurately, and plays a critical role in a series of physiological processes. However, abnormal activation of the reverse mode of NCX plays a vital role in renal ischemia reperfusion injury, which can mediate the overload of cytoplasmic Ca2+, then triggers a series of harmful metabolic reactions that led to cell injury and death. Currently, phenoxyl derivatives that selectively inhibit the reverse mode of NCX have been extensively studied and become new drug targets for the treatment of renal ischemia reperfusion injury.

Key words: sodium calcium exchanger, renal ischemia reperfusion injury, calcium overload, phenoxyl derivatives

CLC Number: